Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis
✍ Scribed by Mika Kurokawa; Naoki Hiramatsu; Tsugiko Oze; Kiyoshi Mochizuki; Takayuki Yakushijin; Nao Kurashige; Yuko Inoue; Takumi Igura; Kazuho Imanaka; Akira Yamada; Masahide Oshita; Hideki Hagiwara; Eiji Mita; Toshifumi Ito; Yoshiaki Inui; Taizo Hijioka; Harumasa Yoshihara; Atsuo Inoue; Yasuharu Imai; Michio Kato; Shinichi Kiso; Tatsuya Kanto; Tetsuo Takehara; Akinori Kasahara; Norio Hayashi
- Book ID
- 118088102
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 201 KB
- Volume
- 39
- Category
- Article
- ISSN
- 1386-6346
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
BACKGROUND. Interferon (IFN) has been reported to have beneficial long term effects that reduce the occurrence of hepatocellular carcinoma (HCC), even in patients who do not have complete responses to IFN. The authors evaluated the effect of retreatment with IFN-␣ on the long term prognoses of those